Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics Inc. has made noteworthy advancements in its clinical pipeline, particularly with VK2735, which demonstrates superior weight loss efficacy compared to competitors, positioning the company favorably in the expanding obesity treatment market. The firm has also secured a significant agreement with CordenPharma, enhancing its production capabilities for VK2735 and indicating a proactive strategy in scaling operations amid a competitive landscape. Furthermore, the company’s exploration into additional therapeutic areas such as Alzheimer’s, hypertension, and MASH, alongside ongoing clinical trial data, supports a positive long-term outlook for Viking's potential value creation.

Viking Therapeutics Inc. faces a negative outlook primarily due to increased research and development spending that has led to a downward revision of the company's price target, indicating financial strain and uncertainty. The potential for negative safety and efficacy findings in late-stage clinical trials raises concerns about the viability of its product pipeline, which could further damage sales projections and market penetration. Additionally, disappointing earnings results, such as a 4Q24 EPS of ($0.32) falling short of estimates, highlight financial performance challenges that may hinder the company's ability to secure adequate funding and progress through critical development phases.